{{Infobox drug
|image=File:Cimetidine Structural Formula V.1.svg
|width=250px
|image2=Cimetidine-xtal-3D-balls.png
|width2=250px
<!--Clinical data-->
|IUPAC_name=1-cyano-2-methyl-3-[2-[(5-methyl-1''H''-imidazol-4-yl)methylsulfanyl]ethyl]guanidine
|Drugs.com={{drugs.com|monograph|cimetidine}}
|MedlinePlus=a682256
|licence_US=Cimetidine
|pregnancy_AU=B1
|pregnancy_US=B
|routes_of_administration=[[口服|口服]]、[[肌肉注射|肌肉注射]]、[[靜脈注射|靜脈注射]]<ref name="GuptaSingh-Radcliff2013" />
<!--Pharmacokinetic data-->
|tradename=Tagamet
|pronounce={{IPAc-en|s|ᵻ|ˈ|m|ɛ|t|ᵻ|d|iː|n}}或{{IPAc-en|s|aɪ|ˈ|m|ɛ|t|ᵻ|d|iː|n}}
|legal_AU=S4
|legal_UK=POM
|legal_US_comment=（200mg口服片為[[非處方藥|非處方藥]]）
|legal_US=Rx-only
|bioavailability=60–70%<ref name="DowdJohnson2016">{{cite book|author1=Frank J. Dowd|author2=Bart Johnson|author3=Angelo Mariotti|title=Pharmacology and Therapeutics for Dentistry - E-Book|url=https://books.google.com/books?id=6xT7DAAAQBAJ&pg=PA406|date=2016-09-03|publisher=Elsevier Health Sciences|isbn=978-0-323-44595-5|pages=406–}}</ref><ref name="LeikinPaloucek1995" />
|protein_bound=13–25%<ref name="LeikinPaloucek1995" /><ref name="AcademicPress1984">{{cite book|title=Profiles of Drug Substances, Excipients and Related Methodology|url=https://books.google.com/books?id=Fz6X-GmS-GgC&pg=PA176|date=1984-10-24|publisher=Academic Press|isbn=978-0-08-086108-1|pages=176–}}</ref>
|metabolism=[[肝臟|肝臟]]<ref name="LeikinPaloucek1995" />
|metabolites=*西咪替丁亞碸<ref name="LeikinPaloucek1995" /><br>
*羥基西咪替丁<ref name="LeikinPaloucek1995" /><br>
*鳥嘌呤脲基西咪替丁<ref name="LeikinPaloucek1995" />
|onset=30分鐘<ref name="VallerandSanoski2016" />
|elimination_half-life=123分鐘（約2小時）<ref name="AcademicPress1984" />
|duration_of_action=4–8小時<ref name="GuptaSingh-Radcliff2013">{{cite book|author1=Anita Gupta|author2=Nina Singh-Radcliff|title=Pharmacology in Anesthesia Practice|url=https://books.google.com/books?id=a85oAgAAQBAJ&pg=PT177|date=2013-03-12|publisher=Oxford University Press|isbn=978-0-19-934399-7|pages=177–}}</ref>
|excretion=[[尿液|尿液]]<ref name="AcademicPress1984" />
<!--Identifiers-->|synonyms=SKF-92334<ref name="Elks2014" />
<!--Chemical data-->
|ATC_prefix=A02
|CAS_number=51481-61-9
|ChEBI=3699
|ChEMBL=30
|ChemSpiderID=2654
|DrugBank=DB00501
|IUPHAR_ligand=1231
|KEGG=D00295
|PubChem=2756
|UNII=80061L1WGD
|ATC_suffix=BA01|
|C=10|H=16|N=6|S=1
|molecular_weight=252.34 g/mol
|SMILES=CC1=C(N=CN1)CSCCNC(=NC)NC#N <ref>https://pubchem.ncbi.nlm.nih.gov/compound/cimetidine</ref>
|smiles=CC1=C(N=CN1)CSCCNC(=NC)NC#N <ref>https://pubchem.ncbi.nlm.nih.gov/compound/cimetidine</ref>
|StdInChI=1S/C10H16N6S/c1-8-9(16-7-15-8)5-17-4-3-13-10(12-2)14-6-11/h7H,3-5H2,1-2H3,(H,15,16)(H2,12,13,14)
|StdInChIKey=AQIXAKUUQRKLND-UHFFFAOYSA-N}}
{{medical}}

'''西咪替丁'''（[[国际非专利药品名称|INN]]：cimetidine），也称'''甲氰咪胍'''、'''西米替丁'''或'''希美得定'''，商品名稱為'''泰胃美'''（'''Tagamet'''），是一種[[组胺|组胺]][[H2受体阻抗剂|H<sub>2</sub>受体阻抗剂]]，主要用於抑制[[胃酸|胃酸]]的分泌<ref name="Elks2014">{{Cite book|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA275|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|last=Elks|first=J.|date=2014-11-14|publisher=Springer|isbn=978-1-4757-2085-3|pages=275–}}</ref><ref name="IndexNominum2000">{{Cite book|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA234|title=Index Nominum 2000: International Drug Directory|date=January 2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=234–}}</ref><ref name="MortonMorton1999">{{Cite book|url=https://books.google.com/books?id=mqaOMOtk61IC&pg=PA77|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|last=Morton|first=Ian|last2=Morton|first2=I. K.|last3=Hall|first3=Judith M.|date=1999-10-31|publisher=Springer Science & Business Media|isbn=978-0-7514-0499-9|pages=77–}}</ref>，並用于治疗[[胃灼热|胃灼热]]和[[消化道溃疡|消化道溃疡]]。<ref name="BurchumRosenthal2014">{{Cite book|url=https://books.google.com/books?id=C7_NBQAAQBAJ&pg=PA952|title=Lehne's Pharmacology for Nursing Care|last=Burchum|first=Jacqueline|last2=Rosenthal|first2=Laura|date=2014-12-02|publisher=Elsevier Health Sciences|isbn=978-0-323-34026-7|pages=952–}}</ref>在[[英国|英国]]，西咪替丁可以作為非處方藥出售给公众（以2周的用量為限），用于16岁以上的成人和儿童短期舒緩[[胃痛|胃痛]]、[[消化不良|消化不良]]、[[胃酸|胃酸]]过多的症状（每次最大用量为200毫克；每天不可用多於800毫克），或用于预防夜间[[胃灼热|胃灼热]]（每晚用量100毫克）。<ref>{{Cite web|url=https://bnf.nice.org.uk/drug/cimetidine.html#exceptionsToLegalCategory|title=CIMETIDINE|last=BNF}}</ref>

自從[[雷尼替丁|雷尼替丁]]、[[法莫替丁|法莫替丁]]等第二代H<sub>2</sub>受体阻抗剂面世以來，[[药物相互作用|药物相互作用]]和[[副作用|副作用]]相對較大的西咪替丁的使用量已有所减少。

西咪替丁在1971年首次發現，並在1977年投入市場。<ref name="FischerGanellin2010">{{Cite book|url=https://books.google.com/books?id=h2Kd8ci4Ln8C&pg=PA4|title=Analogue-based Drug Discovery II|last=Fischer|first=Janos|last2=Ganellin|first2=C. Robin|date=2010-08-24|publisher=John Wiley & Sons|isbn=978-3-527-63212-1|pages=4}}</ref><ref>{{Cite book|url=https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA444|title=Analogue-based Drug Discovery|last=Fischer|first=Janos|last2=Ganellin|first2=C. Robin|date=2006|publisher=John Wiley & Sons|isbn=9783527607495|page=444|language=en}}</ref>西咪替丁在1976年批准在[[英国|英国]]上市，并在1979年由[[美国食品药品监督管理局|美国食品药品监督管理局]]批准在[[美国|美国]]作為处方藥出售。

== 医疗用途 ==
{{Main article|H2受體阻抗劑}}
西咪替丁主要用於抑制[[胃酸|胃酸]]分泌，並用於治療[[胃灼熱|胃灼熱]]和[[消化道潰瘍|消化道潰瘍]]。
=== 其他用途 ===
有些证据表示西咪替丁可能對治療尋常[[疣|疣]]有效；但在更严格的[[双盲|双盲]][[临床试验|临床试验]]中，西咪替丁並不比[[安慰剂|安慰剂]]有效。<ref>{{Cite journal|title=Use of histamine2-antagonists for the treatment of verruca vulgaris|date=July 2007|journal=The Annals of Pharmacotherapy|issue=7|doi=10.1345/aph.1H616|volume=41|pages=1222–6|pmid=17535844}}</ref><ref>{{Cite journal|title=Cimetidine therapy for recalcitrant warts in adults|date=June 1996|journal=Archives of Dermatology|issue=6|doi=10.1001/archderm.1996.03890300108014|volume=132|pages=680–2|pmid=8651718}}</ref><ref>{{Cite journal|title=Is cimetidine effective for nongenital warts: a double-blind, placebo-controlled study|date=April 1997|journal=Archives of Dermatology|issue=4|doi=10.1001/archderm.133.4.533|volume=133|pages=533–4|pmid=9126017}}</ref>

有暂定证据支持西咪替丁作為附加治療對治疗[[大肠癌|大肠癌]]有效。<ref>{{Cite journal|title=Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer|date=2012-08-15|journal=The Cochrane Database of Systematic Reviews|issue=8|doi=10.1002/14651858.CD007814.pub2|volume=8|pages=CD007814|pmid=22895966}}</ref>

西咪替丁能抑制{{Tsl|en|Aminolevulinic_acid_synthase|ALA合成酶}}的活性，因此，西咪替丁在预防和治疗[[紫質症|紫質症]]的急性病發中可能有某些价值。<ref>{{Cite book|url=https://www.ncbi.nlm.nih.gov/books/NBK1193/|title=Acute Intermittent Porphyria|last=Whatley|first=SD|last2=Badminton|first2=MN|last3=Pagon|first3=RA|last4=Adam|first4=MP|last5=Ardinger|first5=HH|last6=Wallace|first6=SE|last7=Amemiya|first7=A|last8=Bean|first8=LJH|last9=Bird|first9=TD|date=2013|pmid=20301372}}</ref><ref>{{Cite book|url=http://fpm.anzca.edu.au/documents/apmse4_2015_final|title=Acute Pain Management: Scientific Evidence|last=Schug, SA; Palmer, GM; Scott, DA; Halliwell, R; Trinca, J; APM:SE Working Group of the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine|date=2015|publisher=Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine|accessdate=2017-09-07|isbn=978-0-9873236-6-8|edition=4th|location=Melbourne, Australia|page=316|format=PDF}}</ref>

== 副作用 ==
西咪替丁的已知[[副作用|副作用]]包括輕微和短暫的[[腹瀉|腹瀉]]、[[皮疹|皮疹]]、[[頭暈|頭暈]]、[[疲勞|疲勞]]、[[便秘|便秘]]和[[肌肉疼痛|肌肉疼痛]]。<ref name="RitterLewis2008">{{Cite book|url=https://books.google.com/books?id=TD59BgAAQBAJ&pg=PA250|title=A Textbook of Clinical Pharmacology and Therapeutics|last=Ritter|first=James|last2=Lewis|first2=Lionel|last3=Mant|first3=Timothy|last4=Ferro|first4=Albert|date=2008-04-25|publisher=CRC Press|isbn=978-1-4441-1300-6|edition=5|pages=250–}}</ref>有报告指老年人服用後可能发生[[譫妄|譫妄]]。<ref name="RitterLewis2008"/>由於其[[激素|激素]]作用，西咪替丁在長期治療期間罕見地導致男性[[性功能障礙|性功能障礙]]，包括[[性慾減退|性慾減退]]、[[勃起功能障礙|勃起功能障礙]]以及[[男性乳房發育症|男性乳房發育症]]（0.1-0.2％）。<ref name="RitterLewis2008"/><ref>{{Cite journal|title=Cimetidine: adverse reactions and acute toxicity|date=February 1981|journal=American Journal of Hospital Pharmacy|issue=2|volume=38|pages=188–97|pmid=7011006}}</ref><ref>{{Cite journal|title=Safety issues relating to long-term treatment with histamine H2-receptor antagonists|journal=Alimentary Pharmacology & Therapeutics|doi=10.1111/j.1365-2036.1993.tb00597.x|year=1993|volume=7 Suppl 2|pages=35–40|pmid=8103374}}</ref>[[间质性肾炎|间质性肾炎]]、[[荨麻疹|荨麻疹]]、[[血管性水肿|血管性水肿]]也可能罕見地發生。<ref name="RitterLewis2008" />西咪替丁也与短暫[[氨基转移酶|氨基转移酶]]活动上升有關，但{{tsl|en|Hepatotoxicity|肝中毒}}是罕见的。<ref name="Kelly2009" />

== 过量 ==
西咪替丁似乎在[[藥物過量|過量服用]]時相對安全，即使服用過量（例如20克）也不會產生任何[[症狀|症狀]]。<ref name="Dart2004"/>

== 药物相互作用 ==
由於西咪替丁對[[細胞色素P450|細胞色素P450]][[酶|酶]]的非選擇性[[抑制|抑制]]，它具有許多[[藥物相互作用|藥物相互作用]]。示例包括：

* 西咪替丁影響[[美沙酮|美沙酮]]的代謝，有時導致血液濃度上升和更多的副作用，並且可能與抗[[瘧疾|瘧疾]]藥物[[羥氯喹|羥氯喹]]相互作用。<ref>{{Cite journal|title=Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases|date=June 1996|journal=Lupus|doi=10.1177/096120339600500104|volume=5 Suppl 1|pages=S11-5|pmid=8803904}}</ref>
* 西咪替丁還可以與許多精神科藥物相互作用，包括[[三环类抗抑郁药|三环类抗抑郁药]]和[[选择性5-羟色胺再摄取抑制剂|选择性5-羟色胺再摄取抑制剂]] ，導致這些藥物的血液濃度上升和隨後毒性的可能性。
* 給予西咪替丁後，[[佐米曲普坦|佐米曲普坦]]及其活性代謝物的[[消除半衰期|消除半衰期]]和{{tsl|en|Area_under_the_curve_(pharmacokinetics)|曲线下面積}}大約增加了一倍。<ref>See complete drug interactions for Zomig (zolmitriptan succinate used for migraine relief) in package insert: {{Cite web|url=http://www1.astrazeneca-us.com/pi/Zomig.pdf|title=Highlights of Zomig Prescribing Information|publisher=AstraZeneca|access-date=2018-09-02|archive-url=https://web.archive.org/web/20150218190357/http://www1.astrazeneca-us.com/pi/Zomig.pdf|archive-date=2015-02-18|dead-url=yes}}</ref>
* 西咪替丁是管狀[[肌酸酐|肌酸酐]]分泌的強抑製劑。 肌酐是[[肌酸|肌酸]]分解的副產物，而肌酐的累積與[[尿毒症|尿毒症]]有關 ，但肌酐累積的症狀尚不清楚，因為它們難以與其他含氮廢物堆積物分離。<ref>{{Cite journal|title=Transcellular transport of creatinine in renal tubular epithelial cell line LLC-PK1|date=June 2005|journal=Drug Metabolism and Pharmacokinetics|issue=3|doi=10.2133/dmpk.20.200|volume=20|pages=200–5|pmid=15988122}}</ref>
* 有如[[紅黴素|紅黴素]]一樣，西咪替丁干擾身體對[[西地那非|西地那非]]的代謝，導致其強度和持續時間增加（因此其副作用更為突出）。
* 西咪替丁已證實與CYP1A2受質[[茶鹼|茶鹼]]、CYP2C9受質{{tsl|en|Tolbutamide|甲苯磺丁脲}}、CYP2D6受質{{tsl|en|Desipramine|地昔帕明}}和CYP3A4受質[[三唑侖|三唑侖]]具顯著的藥物相互作用，並且與這些酶的其他受質可能有相互作用。<ref name="Rodrigues2008">{{Cite book|url=https://books.google.com/books?id=rmCGQ8qAv8AC&pg=PA294|title=Drug-Drug Interactions, Second Edition|last=Rodrigues|first=A. David|date=2008-02-08|publisher=CRC Press|isbn=978-0-8493-7594-1|pages=277, 294}}</ref>
* 西咪替丁已證實減低人體中[[米氮平|米氮平]]、{{tsl|en|Imipramine|丙咪嗪}}、{{tsl|en|timolol|噻嗎洛爾}}、{{tsl|en|nebivolol|奈必洛爾}}、{{tsl|en|sparteine|司巴丁}}、[[氯雷他定|氯雷他定]]、{{tsl|en|Nortriptyline|去甲替林}}、[[加巴噴丁|加巴噴丁]]和{{tsl|en|Desipramine|地昔帕明}}的清除率。<ref name="Zhou2016" />
* 西咪替丁抑制[[二甲雙胍|二甲雙胍]]和[[普魯卡因胺|普魯卡因胺]]的腎排泄，導致這些藥物的循環水平增加。<ref name="RitterLewis2008" />
* 西咪替丁臨床上重要的相互作用包括與[[華法林|華法林]]、[[茶鹼|茶鹼]]、[[苯妥英|苯妥英]]、[[卡馬西平|卡馬西平]]、[[哌替啶|哌替啶]]和其他[[鴉片類藥物|鴉片類藥物]]、[[三環類抗抑鬱藥|三環類抗抑鬱藥]]、[[利多卡因|利多卡因]]、{{tsl|en|Terfenadine|特非那定}}、[[胺碘酮|胺碘酮]]、{{tsl|en|Flecainide|氟卡尼}}、[[奎尼丁|奎尼丁]]、[[氟尿嘧啶|氟尿嘧啶]]和[[苯二氮䓬类|苯二氮䓬类]]藥物的相互作用。<ref name="RosenfeldLoose2007" /><ref name="RitterLewis2008" />
* 西咪替丁降低作為[[前體藥物|前體藥物]]的CYP2D6受質的作用，例如[[可待因|可待因]]、[[曲馬多|曲馬多]]和[[他莫昔芬|他莫昔芬]]。<ref name="FullerSajatovic2005">{{Cite book|url=https://books.google.com/books?id=LzBtAAAAMAAJ|title=Drug Information Handbook for Psychiatry|last=Fuller|first=Matthew A.|last2=Sajatovic|first2=Martha|publisher=Lexi-Comp|year=2005|page=285}}</ref>
* 西咪替丁降低了口服[[酮康唑|酮康唑]]和[[伊曲康唑|伊曲康唑]]的吸收，因它們的吸收需要低pH值。<ref name="RitterLewis2008" />
* 西咪替丁在[[對乙醯氨基酚中毒|對乙醯氨基酚中毒]]方面具有理論上但未經證實的益處。<ref name="Kelly2009" />這是因為乙醯氨基酚的肝毒性代謝產物{{tsl|en|NAPQI}}是經由肝細胞色素P450系統（特別是CYP1A2，CYP2E1和CYP3A4）產生的。<ref name="CameronFeuer2012">{{Cite book|url=https://books.google.com/books?id=xZf-CAAAQBAJ&pg=PA140|title=Drug-Induced Hepatotoxicity|last=Cameron|first=Ross|last2=Feuer|first2=George|last3=de la Iglesias|first3=Felix|date=2012-12-06|publisher=Springer Science & Business Media|isbn=978-3-642-61013-4|pages=140–}}</ref>

== 药理学 ==

=== 作用機理 ===

==== 组织胺H<sub>2</sub>受体的拮抗 ====
西咪替丁作为[[抗酸药|抗酸药]]的機理是作为[[组胺|组胺]]H<sub>2</sub>受体的[[拮抗劑|拮抗劑]]。<ref name="pmid6317740">{{Cite journal|title=Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine|journal=Journal of Clinical Gastroenterology|doi=10.1097/00004836-198312001-00008|year=1983|volume=5 Suppl 1|pages=81–90|pmid=6317740}}</ref>它以42nM的K<sub>d</sub>結合H<sub>2</sub>受體。<ref name="Osborne2013">{{Cite book|url=https://books.google.com/books?id=ldnWAgAAQBAJ&pg=PA297|title=Selected Topics from Neurochemistry|last=Neville N. Osborne|date=2013-10-22|publisher=Elsevier Science|isbn=978-1-4832-8635-8|pages=297–}}</ref>

==== 抑制细胞色素P450酶 ====
西咪替丁是某些[[細胞色素P450|細胞色素P450]]酶的有效抑制劑，<ref name="Dart2004">{{Cite book|url=https://books.google.com/books?id=BfdighlyGiwC&pg=PA402|title=Medical Toxicology|last=Dart|first=Richard C.|publisher=Lippincott Williams & Wilkins|year=2004|isbn=978-0-7817-2845-4|pages=402–}}</ref><ref name="LemkeWilliams2008">{{Cite book|url=https://books.google.com/books?id=R0W1ErpsQpkC&pg=PA273|title=Foye's Principles of Medicinal Chemistry|last=Lemke|first=Thomas L.|last2=Williams|first2=David A.|publisher=Lippincott Williams & Wilkins|year=2008|isbn=978-0-7817-6879-5|pages=273–}}</ref>其中包括[[CYP1A2|CYP1A2]]、[[CYP2C9|CYP2C9]]、[[CYP2C19|CYP2C19]]、[[CYP2D6|CYP2D6]]、{{tsl|en|CYP2E1}}和[[CYP3A4|CYP3A4]]。<ref name="KarallieddeClarke2010">{{Cite book|url=https://books.google.com/books?id=B2YwH371uzYC&pg=PA633|title=Adverse Drug Interactions: A Handbook for Prescribers|last=Karalliedde|first=Lakshman Delgoda|last2=Clarke|first2=Simon F.J.|last3=Collignon|first3=Ursula|last4=Karalliedde|first4=Janaka|date=2010-01-29|publisher=CRC Press|isbn=978-0-340-92769-4|pages=633–}}</ref>西咪替丁似乎主要是CYP1A2、CYP2D6和CYP3A4<ref name="PriskornLarsen1997">{{Cite journal|title=Pharmacokinetic interaction study of citalopram and cimetidine in healthy subjects|journal=European Journal of Clinical Pharmacology|issue=3|doi=10.1007/s002280050282|year=1997|volume=52|pages=241–2|pmid=9218934}}</ref>的中度抑制剂。<ref name="VallerandSanoski2016">{{Cite book|url=https://books.google.com/books?id=ORa1DAAAQBAJ&pg=PA636|title=Davis's Drug Guide for Nurses|last=Vallerand|first=April Hazard|last2=Sanoski|first2=Cynthia A|last3=Deglin|first3=Judith Hopfer|date=2016-05-25|publisher=F.A. Davis|isbn=978-0-8036-5779-3|pages=636–}}</ref>這是值得注意的，因為這三種CYP450[[同工酶|同工酶]]參與CYP450介導的[[生物轉化作用|生物轉化作用]]。<ref name="MartinezAlbet1999">{{Cite journal|title=Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists|date=April 1999|journal=Clinical Pharmacology and Therapeutics|issue=4|doi=10.1016/S0009-9236(99)70129-3|volume=65|pages=369–76|pmid=10223772}}</ref>然而，CYP1A2、CYP2C9、CYP2C19、CYP2D6、CYP2E1和CYP3A4也牽涉在許多常用藥物的氧化[[代謝|代謝]]中。<ref name="Delafuente2003">{{Cite journal|title=Understanding and preventing drug interactions in elderly patients|date=November 2003|journal=Critical Reviews in Oncology/Hematology|issue=2|doi=10.1016/j.critrevonc.2003.04.004|volume=48|pages=133–43|pmid=14607376}}</ref>因此西咪替丁與其他藥物一起服用時，可能會產生許多[[药物相互作用|药物相互作用]]。

西咪替丁已知是幾種CYP450酶的可逆性和[[競爭性抑制劑|競爭性抑制劑]]，<ref name="Kelly2009">{{Cite book|url=https://books.google.com/books?id=z7nO3OrNXckC&pg=PA224|title=Diseases of the Liver and Biliary System in Children|last=Kelly|first=Deirdre|date=2009-01-26|publisher=John Wiley & Sons|isbn=978-1-4443-0054-3|pages=224–}}</ref><ref name="RosenfeldLoose2007">{{Cite book|url=https://books.google.com/books?id=fm8kmMDjdiAC&pg=PA202|title=Pharmacology|last=Rosenfeld|first=Gary C.|last2=Loose|first2=David S.|publisher=Lippincott Williams & Wilkins|year=2007|isbn=978-0-7817-8074-2|pages=202–}}</ref><ref name="Cairns2012">{{Cite book|url=https://books.google.com/books?id=gNliFkwHYgEC&pg=PA110|title=Essentials of Pharmaceutical Chemistry|last=Cairns|first=Donald|publisher=Pharmaceutical Press|year=2012|isbn=978-0-85369-979-8|pages=110–}}</ref>也是CYP2D6的{{link-en|自殺型抑制劑|Suicide inhibition}}，可造成不可逆的抑制。<ref name="Zhou2016">{{Cite book|url=https://books.google.com/books?id=UJqmCwAAQBAJ&pg=PA299|title=Cytochrome P450 2D6: Structure, Function, Regulation and Polymorphism|last=Shufeng Zhou|date=2016-04-06|publisher=CRC Press|isbn=978-1-4665-9788-4|pages=299–}}</ref>西咪替丁[[咪唑|咪唑]]環的[[氮|氮]]原子能直接與[[活性位點|活性位點]]的絡合[[血紅素|血紅素]][[鐵|鐵]]結合，從而可逆地抑制CYP450酶，阻斷其他藥物的氧化。<ref name="pmid9630736">{{Cite journal|title=The detoxification enzyme systems|date=June 1998|journal=Alternative Medicine Review|issue=3|volume=3|pages=187–98|pmid=9630736}}</ref>

==== 抗雄激素和雌激素作用 ====
已知高劑量西咪替丁具有弱的[[抗雄激素|抗雄激素]]活性。<ref name="Becker2001">{{Cite book|url=https://books.google.com/books?id=FVfzRvaucq8C&pg=PA1196|title=Principles and Practice of Endocrinology and Metabolism|last=Becker|first=Kenneth L.|publisher=Lippincott Williams & Wilkins|year=2001|isbn=978-0-7817-1750-2|pages=1196–}}</ref><ref name="pmid6150641">{{Cite journal|title=Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric hypersecretory states|date=November 1984|journal=The American Journal of Medicine|issue=5B|volume=77|pages=90–105|pmid=6150641}}</ref><ref name="pmid3921876">{{Cite journal|title=[Dysfunction of the hypothalamo-hypophyseal-gonadal axis induced by histamine H2 antagonists. Review of the literature and personal observations]|date=March 1985|journal=Minerva Medica|issue=12|volume=76|pages=579–86|language=it|pmid=3921876}}</ref>它作為[[受體拮抗劑|受體拮抗劑]]，可以直接和競爭性地結合[[雄激素受體|雄激素受體]]，以阻斷[[睪酮|睪酮]]與[[二氫睪酮|二氫睪酮]]等雄激素的作用。<ref name="pmid428705">{{Cite journal|title=Cimetidine is an antiandrogen in the rat|date=March 1979|journal=Gastroenterology|issue=3|volume=76|pages=504–8|pmid=428705}}</ref><ref name="pmid6123322">{{Cite journal|title=The effects of histamine H2 receptor antagonists on androgen action in vivo and dihydrotestosterone binding to the rat prostate androgen receptor in vitro|url=http://linkinghub.elsevier.com/retrieve/pii/0006-2952(82)90449-X|date=March 1982|journal=Biochemical Pharmacology|issue=5|doi=10.1016/0006-2952(82)90449-X|volume=31|pages=677–84|pmid=6123322}}</ref>然而西咪替丁對雄激素受體的[[親和力|親和力]]非常弱。根據一項研究所示，它對人雄激素受體的親和力僅有人工合成[[同化激素|同化激素]]{{tsl|en|metribolone}}的0.00084%。<ref name="pmid6725525">{{Cite journal|title=The use of human skin fibroblasts to obtain potency estimates of drug binding to androgen receptors|date=July 1984|journal=J. Clin. Endocrinol. Metab.|issue=1|doi=10.1210/jcem-59-1-51|volume=59|pages=51–5|pmid=6725525}}</ref>無論如何，在足夠高的劑量下，西咪替丁在動物體內表現出微弱但顯著的抗雄激素作用，包括[[大鼠|大鼠]]腹側[[前列腺|前列腺]]和[[小鼠|小鼠]][[腎臟|腎臟]]的抗雄激素作用；大鼠上如[[前列腺|前列腺]]和[[精囊|精囊]]等{{tsl|en|male accessory glands|雄性附屬腺體}}質量減少；和雄性大鼠中{{tsl|en|Gonadotropin|促性腺激素}}水平升高（由於雄激素對HPG軸的[[負反饋|負反饋]]減少）。<ref name="GerallMoltz2013" /><ref name="PlessisAgarwal2014">{{cite book|author1=Stefan S. du Plessis|author2=Ashok Agarwal|author3=Edmund S. Sabanegh, Jr.|title=Male Infertility: A Complete Guide to Lifestyle and Environmental Factors|url=https://books.google.com/books?id=-I4kBAAAQBAJ&pg=PA233|date=2014-07-26|publisher=Springer|isbn=978-1-4939-1040-3|pages=233–}}</ref>除了雄激素受體拮抗作用外，已知西咪替丁能通過抑制參與雌二醇代謝失活的CYP450酶，從而抑制[[雌二醇|雌二醇]]的2-[[羥基|羥基]]化，導致[[雌激素|雌激素]]水平增加。<ref name="pmid2747769">{{cite journal | vauthors = Galbraith RA, Michnovicz JJ | title = The effects of cimetidine on the oxidative metabolism of estradiol | journal = The New England Journal of Medicine | volume = 321 | issue = 5 | pages = 269–74 | date = August 1989 | pmid = 2747769 | doi = 10.1056/NEJM198908033210501 | url = http://www.nejm.org/doi/abs/10.1056/NEJM198908033210501?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed }}</ref><ref name="pmid1988774">{{cite journal | vauthors = Michnovicz JJ, Galbraith RA | title = Cimetidine inhibits catechol estrogen metabolism in women | journal = Metabolism | volume = 40 | issue = 2 | pages = 170–4 | date = February 1991 | pmid = 1988774 | doi = 10.1016/0026-0495(91)90169-W }}</ref><ref name="PescovitzWalvoord2007">{{cite book | first1 = Ora H. | last1 = Pescovitz | first2 = Emily C. | last2 = Walvoord | name-list-format = vanc | title = When Puberty is Precocious: Scientific and Clinical Aspects | url = https://books.google.com/books?id=seYO1f1JgzYC&pg=PA203 | date = 2007-06-06 | publisher = Springer Science & Business Media | isbn = 978-1-59745-499-5 | pages = 203– }}</ref><ref name="PolatCuhaci2014">{{cite journal | vauthors = Cuhaci N, Polat SB, Evranos B, Ersoy R, Cakir B | title = Gynecomastia: Clinical evaluation and management | journal = Indian Journal of Endocrinology and Metabolism | volume = 18 | issue = 2 | pages = 150–8 | date = March 2014 | pmid = 24741509 | doi = 10.4103/2230-8210.129104 | pmc=3987263}}</ref><ref name="RendicCarlo2010">{{cite journal | vauthors = Rendic S, Di Carlo FJ | title = Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors | journal = Drug Metabolism Reviews | volume = 29 | issue = 1-2 | pages = 413–580 | year = 2010 | pmid = 9187528 | doi = 10.3109/03602539709037591 }}</ref><ref name="GalbraithMichnovicz1989">{{cite journal | vauthors = Galbraith RA, Michnovicz JJ | title = The effects of cimetidine on the oxidative metabolism of estradiol | journal = The New England Journal of Medicine | volume = 321 | issue = 5 | pages = 269–74 | date = August 1989 | pmid = 2747769 | doi = 10.1056/NEJM198908033210501 }}</ref>有報告指，西咪替丁可以減少[[睾酮|睾酮]]合成，並增加[[催乳素|催乳素]]水平，這可能是[[雌激素|雌激素]]水平上升的繼發性因素。<ref name="pmid22862307">{{cite journal | vauthors = Deepinder F, Braunstein GD | title = Drug-induced gynecomastia: an evidence-based review | journal = Expert Opin Drug Saf | volume = 11 | issue = 5 | pages = 779–95 | date = September 2012 | pmid = 22862307 | doi = 10.1517/14740338.2012.712109 | url = }}</ref>

在用於治療的濃度下，西咪替丁對男性的循環內睾酮濃度沒有影響或僅有輕微上升<ref name="GerallMoltz2013" />，睾酮水平的增加可能是因為雄激素受體拮抗作用，造成{{link-en|HPG軸|Hypothalamic–pituitary–gonadal axis}}上的[[負反饋|負反饋]]機制的喪失。<ref name="GerallMoltz2013" /><ref name="PlessisAgarwal2014" />在典型用於治療消化性潰瘍的臨床劑量下，西咪替丁所引致的[[男性乳房發育症|男性乳房發育症]]的發生率低於1%。<ref name="WattsFaingold2009">{{cite book|author1=Stephanie Watts|author2=Carl Faingold|author3=George Dunaway|author4=Lynn Crespo|title=Brody's Human Pharmacology - E-Book|url=https://books.google.com/books?id=kfsrz_-OrMQC&pg=PA472|date=2009-04-01|publisher=Elsevier Health Sciences|isbn=0-323-07575-4|pages=472–}}</ref><ref name="GerallMoltz2013">{{cite book|author1=Arnold A. Gerall|author2=Howard Moltz|author3=Ingeborg L. Ward|title=Sexual Differentiation|url=https://books.google.com/books?id=4nb1BwAAQBAJ&pg=PA207|date=2013-11-11|publisher=Springer Science & Business Media|isbn=978-1-4899-2453-7|pages=207–}}</ref>在一項對超過9,000名服用西咪替丁的患者進行的調查中，男性乳房發育症是最常見的[[內分泌|內分泌]]相關副作用，但僅有0.2%的患者報告自己受該副作用影響。<ref name="GerallMoltz2013" />但在用於治療{{tsl|en|Zollinger–Ellison_syndrome|佐埃二氏症}}的高劑量時，西咪替丁可能有更高的男性乳房發育症發病率。<ref name="WattsFaingold2009" />在一項小型研究中，在25名接受每天1600mg西咪替丁治療的男性十二指腸潰瘍患者中，他們的男性乳房發育症發病率為20%。<ref name="pmid22862307" />症狀在治療4個月後出現，並在停用西咪替丁後一個月內消退。<ref name="pmid22862307" />在另一項小型研究中，在接受過西咪替丁治療的22名男性中，有60%病人患有由西咪替丁引起的[[乳房|乳房]]病變和[[勃起功能障礙|勃起功能障礙]]。<ref name="pmid22862307" />當病人轉用[[雷尼替丁|雷尼替丁]]時，這些不良反應都得到徹底解決。<ref name="pmid22862307" />對包含超過80,000名男性的[[英國|英國]]{{tsl|en|Clinical Practice Research Datalink#General Practice Research Database|全科醫學研究數據庫}}進行的一項研究發現，與非使用者相比，西咪替丁使用者中男性乳房發育症的相對風險為7.2；<ref name="pmid22862307" />而在服用西咪替丁大於或等於1,000毫克的男性當中，男性乳房發育症的風險是非使用者的40倍以上。<ref name="pmid22862307" />病人在連續用藥後7至12個月期間風險最高。<ref name="pmid22862307" />與西咪替丁相關的男性乳房發育症可歸因於乳房組織中雄激素受體的拮抗，導致雌激素在乳房組織中的作用不受雄激素的影響，雖然因代謝遭抑制而增加的雌激素水平也是可能的機制。<ref name="pmid22862307" />在一些研究中，西咪替丁還與男性的{{tsl|en|Oligospermia|少精子症}}和[[性功能障礙|性功能障礙]]有關。<ref name="PlessisAgarwal2014" /><ref name="GerallMoltz2013" /><ref name="pmid22862307" />

由於西咪替丁對雄激素受體的拮抗非常弱，西咪替丁在治療女性[[多毛症|多毛症]]和{{tsl|en|Hyperandrogenism|雄激素過多症}}等{{tsl|en|Androgen-dependent_condition|雄激素相關病症}}的效果並不佳。<ref name="AltchekDeligdisch2003">{{cite book|author1=Albert Altchek|author2=Liane Deligdisch|author3=Nathan Kase|title=Diagnosis and Management of Ovarian Disorders|url=https://books.google.com/books?id=vds_TQpTIhoC&pg=PA351|date=2003-09-04|publisher=Academic Press|isbn=978-0-08-049451-7|pages=351–}}</ref><ref name="PreglerDeCherney2002">{{cite book|author1=Janet P. Pregler|author2=Alan H. DeCherney|title=Women's Health: Principles and Clinical Practice|url=https://books.google.com/books?id=zC99_it1C5YC&pg=PA595|year=2002|publisher=PMPH-USA|isbn=978-1-55009-170-0|pages=595–}}</ref><ref name="WattsFaingold2009" />因此西咪替丁並不適合用於治療此等病症。<ref name="PreglerDeCherney2002" />

=== 药代动力学 ===
無論[[給藥途徑|給藥途徑]]為何，西咪替丁都能被迅速吸收。<ref name="AcademicPress1984" />西咪替丁的[[口服|口服]][[生物利用度|生物利用度]]是60％至70％。<ref name="DowdJohnson2016" /><ref name="LeikinPaloucek1995" /> 口服西咪替丁可在30分鐘後起效<ref name="VallerandSanoski2016" />，並在1至3小时內達到濃度高峰。<ref name="DowdJohnson2016" />西咪替丁能在體內所有[[组织_(生物学)|组织]]广泛分布。<ref name="AcademicPress1984" />它能夠穿過[[血腦屏障|血腦屏障]]並且可以在[[中樞神經系統|中樞神經系統]]產生作用（例如：[[頭痛|頭痛]]、[[頭暈|頭暈]]、[[嗜睡|嗜睡]]）。<ref name="GuptaSingh-Radcliff2013" />西咪替丁的[[分佈體積|分佈體積]]在成人中為0.8L/ kg，而在兒童中為1.2至2.1L/kg。<ref name="LeikinPaloucek1995">{{Cite book|url=https://books.google.com/books?id=JpZrAAAAMAAJ|title=Poisoning & Toxicology Handbook, 1995-1996|last=Jerrold B. Leikin|last2=Frank P. Paloucek|publisher=Lexi-Comp, Incorporated|year=1995|isbn=978-0-916589-08-0|page=184}}</ref>西咪替丁的[[血漿蛋白結合|血漿蛋白結合]]度為13％至25％，但據說沒有藥理學意義。<ref name="LeikinPaloucek1995" /><ref name="AcademicPress1984" />西咪替丁的[[代謝|代謝]]相對較少，有56％至85％的西咪替丁會在服用後不變地[[排泄|排泄]]出來。<ref name="AcademicPress1984" />它在[[肝臟|肝臟]]中代謝為西咪替丁[[亞砜|亞砜]]、[[羥基|羥基]]西咪替丁和[[鳥嘌呤|鳥嘌呤]][[脲|脲]]基西咪替丁。<ref name="LeikinPaloucek1995" />而西咪替丁的主要[[代謝產物|代謝產物]]是亞砜，約佔排泄物質的30％。<ref name="AcademicPress1984" />西咪替丁能被迅速消除，[[消除半衰期|消除半衰期]]為123分鐘，並主要從尿液中排泄出來。<ref name="AcademicPress1984" />西咪替丁的作用時間為4至8小時。<ref name="GuptaSingh-Radcliff2013" /><ref name="AcademicPress1984" />

== 历史 ==
雖然只被FDA批准用於抑制胃酸分泌，西咪替丁已被提倡用於許多的皮膚病中。<ref>{{Cite journal|title=Cimetidine: a review of the recent developments and reports in cutaneous medicine|date=March 2003|journal=Dermatology Online Journal|issue=2|volume=9|pages=4|pmid=12639457}}</ref>西咪替丁是典型的组胺[[H2受体阻抗剂|H<sub>2</sub>受体阻抗剂]]，並且是其他H<sub>2</sub>受體阻抗劑的原型。西咪替丁是由[[詹姆士·W·布拉克|詹姆士·W·布拉克]]、{{tsl|en|C. Robin Ganellin}}等人在現為[[葛蘭素史克|葛蘭素史克]]的SK&F實驗室的研發成果。<ref name="ACS Landmarks">{{Cite web|url=http://portal.acs.org/portal/PublicWebSite/education/whatischemistry/landmarks/cimetidinetagamet/|title=Tagamet<sup>®</sup>: Discovery of Histamine H<sub>2</sub>-receptor Antagonists|accessdate=2012-06-25|work=National Historic Chemical Landmarks|publisher=American Chemical Society|archiveurl=https://archive.is/20121209003707/http://portal.acs.org/portal/PublicWebSite/education/whatischemistry/landmarks/cimetidinetagamet/|archivedate=2012-12-09}}</ref>這是使用理性[[藥物設計|藥物設計]]方法發現的首批藥物。[[詹姆士·W·布拉克|詹姆士·W·布拉克]]爵士因發現[[普萘洛爾|普萘洛爾]]與西咪替丁而獲得1988年的[[諾貝爾生理學或醫學獎|諾貝爾生理學或醫學獎]]。

早在1964年，人們就知道[[組織胺|組織胺]]會促進胃酸的分泌，但傳統的抗組織胺藥物對胃酸分泌沒有影響。SK&F的科學家因而假設有兩個組織胺受體的存在。H<sub>1</sub>是傳統的組織胺受體；H<sub>2</sub>為刺激胃酸分泌的組織胺受體。SK&F團隊用組織胺的結構進行一系列的設計。合成了數百個修飾過的化合物，試圖阻斷這個完全未知的H<sub>2</sub>受體上。第一个突破是N<sup>α</sup>-脒基组胺，為不完全的H<sub>2</sub>受體阻抗劑。而後又根據此物重新定義受體且合成出{{le|布立馬胺|burimamide}}，比N<sup>α</sup>-脒基组胺強100倍且是一個H<sub>2</sub>受體的[[競爭性拮抗劑|競爭性拮抗劑]]，從此證實了H<sub>2</sub>受體的存在。

{{le|布立馬胺|burimamide}}在口服給藥時仍然不夠有效，因此基於改變化合物的[[pKa|pKa]]而進一步改變結構，並發現了{{le|Metiamide}}。雖然Metiamide有效，但它的[[腎|腎]]毒性和[[粒細胞|粒細胞]]缺乏症這項副作用卻令人不可接受。由於Metiamide的毒性來自[[硫脲|硫脲]]基團，他們又研究了[[胍|胍]]類似物，最終發現西咪替丁。西咪替丁於1972年合成，並於1973年通過了毒理學評估。

西咪替丁於1976年首次在[[英國|英國]]上市，1977年8月在[[美國|美國]]上市；因此，從開始研發H<sub>2</sub>受體阻抗劑起，就花了12年才開始商業化。到1979年，西咪替丁已在100多個國家上市，成為美國，[[加拿大|加拿大]]和其他幾個國家最暢銷的處方藥。1997年11月，[[美國化學學會|美國化學學會]]和[[英國皇家化學學會|英國皇家化學學會]]在英國[[哈洛|哈洛]]的SmithKline Beecham研究設施揭幕儀式上，將西咪替丁的成功研發稱為藥物史上重要的一頁，並將其歸為其中一項國際化學史里程碑（International Historic Chemical Landmark）。<ref name="Freemantle">{{Cite web|url=http://pubs.acs.org/cen/coverstory/83/8325/8325tagamet.html|title=Tagamet|accessdate=2013-07-01|last=Fremantle|first=Michael|work=Chemical and Engineering news}}</ref>

西咪替丁的商品名稱Tagamet是antagonist和cimetidine兩詞的[[混成詞|混成詞]]。<ref name="ACS Landmarks"/>在西咪替丁引入美國市場後，又有[[雷尼替丁|雷尼替丁]]和[[法莫替丁|法莫替丁]]這兩種H<sub>2</sub>受體阻抗劑被批准。西咪替丁成為有史以來第一種每年銷售額超過10億美元的藥物。<ref>{{Cite news|url=http://www.guernicamag.com/features/111/me_too_drugs/|title=Pharmaceutical Sales 101: Me-Too Drugs|last=Whitney|first=Jake|date=February 2006|work=[[Guernica_Magazine|Guernica]]|accessdate=2008-07-31|deadurl=yes|archiveurl=https://web.archive.org/web/20080807114344/http://www.guernicamag.com/features/111/me_too_drugs/|archivedate=2008-08-07}}</ref>

在2012年，[[葛兰素史克|葛兰素史克]]向{{le|Prestige Brands}}出售Tagamet和其他16个品牌。<ref>{{Cite news|url=http://blogs.newsobserver.com/business/gsk-sells-bc-goodys-and-other-brands|title=GSK sells BC, Goody's and other brands|last=Ranii|first=David|date=2011-12-21|work=[[News_&_Observer|News & Observer]]|deadurl=yes|archiveurl=https://web.archive.org/web/20120415192244/http://blogs.newsobserver.com/business/gsk-sells-bc-goodys-and-other-brands|archivedate=2012-04-15}}</ref>

西咪替丁現已在很大程度上被[[質子泵抑製劑|質子泵抑製劑]]所取代；但在許多國家，西咪替丁都可以作為治療[[胃灼熱|胃灼熱]]的[[非處方藥|非處方藥]]使用。<ref name="Freemantle"/>

== 参考文献 ==
{{Reflist|33em}}

== 外部連結 ==
* [https://archive.is/20121209003707/http://portal.acs.org/portal/PublicWebSite/education/whatischemistry/landmarks/cimetidinetagamet/ Tagamet<sup>®</sup>: Discovery of Histamine H<sub>2</sub>-receptor Antagonists] [[美国化学学会|美国化学学会]] 國家歷史化學地標
{{Drugs for peptic ulcer and GORD}}
{{Histaminergics}}
{{Androgen receptor modulators}}
{{GlaxoSmithKline}}

[[Category:胍|Category:胍]]
[[Category:H2受体拮抗剂|Category:H2受体拮抗剂]]
[[Category:咪唑|Category:咪唑]]
[[Category:硫醚|Category:硫醚]]
[[Category:马用药|Category:马用药]]
[[Category:葛兰素史克|Category:葛兰素史克]]
[[Category:腈|Category:腈]]
[[Category:细胞色素P450|Category:细胞色素P450]]